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ABSTRACT
Background: Suplatast tosilate is a type 2 (Th2) cytokine inhibitor that blocks the production of IgE antibodies
and the invasion of tissues by eosinophils during an allergic reaction. Suplatast tosilate ameliorates asthma
symptoms and airway hypersensitivity by inhibiting production of the Th2 cytokines interleukin (IL)-4 and IL-5．
Methods: In the present study, a comparative examination of the therapeutic effects of suplatast tosilate was
carried out in patients with mild intermittent and mild persistent asthma by randomly allocating 35 adult patients
to a suplatast tosilate group (n = 18 ; 100 mg suplatast tosilate three times daily) and a beclomethasone
dipropionate (BDP) group (n = 17 ; 200 µg BDP twice daily) for 6 weeks of treatment.
Results: The suplatast tosilate group required more time than the BDP group to show improvement in peak
expiratory flow, but at week 6 the change from baseline was nearly the same in both groups. A significant im-
provement was observed for both groups in the peripheral blood eosinophil ratio, serum eosinophil cationic pro-
tein (ECP) levels, induced sputum ECP levels, forced expiratory volume in 1 second, and airway hypersensitiv-
ity, but induced sputum ECP level was lower in the BDP group than in the suplatast tosilate group. Total IgE
levels decreased in the suplatast tosilate group only．
Conclusions: We conclude that suplatast tosilate may be useful inlong-term management of mild bronchial
asthma．
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INTRODUCTION
The Type 2 helper T cell (Th2) cytokines interleukin
(IL)-4 and IL-5 are known to be involved in the modu-
lation of immunoglobulin E (IgE) production by B
cells, as well as in the differentiation, proliferation,
and activation of eosinophils.1 Suplatast tosilate, a di-
methylsulfonium anti-allergy drug that block IgE anti-
body production and eosinophilict issue invasion by
inhibiting the Th2 cytokines IL-4 and IL-5, is associ-
ated with clinical improvement of asthma symptoms
and reductions in airway hypersensitivity.2,3
In recent years , supplementary treatment with
suplatast tosilate has been reported useful in decreas-
ing steroid dosage for patients with severe asthma.4
Researchers have also reported that in patients suffer-
ing from mild intermittent and mild persistent bron-
chial asthma, suplatast tosilate inhibited eosinophilic
airway inflamation and thus reduced airway hyper-
sensitivity . These effects wereparticularly pro-
nounced in atopic asthma.5 However, there are only a
few studies available that compare the usefulness of
suplatast to inhaled steroids.
The present study is a prospective randomized
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Fig. 1　Study design.
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Table 1 Characteristics
p valueBDP (n = 17)Suplatast tosilate (n = 18)
n.s.
75Sex: Male
1013Female
n.s.57 ± 449 ± 4Mean age
n.s.13.1 ± 8.612.0 ± 6.4Mean asthma duration
n.s.
98Atopic status: Atopic
810Non-atopic
n.s.
76Asthma severity: Step 1
1012Step 2
n.s.336.0 ± 42.7372.8 ± 30.2PEF (baseline) (L/min)
n.s.1963.3 ± 130.62328.3 ± 133.3FEV1.0 (baseline) (ml)
n.s.211.8 ± 127.9184.8 ± 112.2Total lgE levels (IU/ml)
BDP: beclomethasone dipropionate, PEF: peak expiratory flow, FEV1.0: forced expiratory volume in 1 s
comparing the usefulness of suplatast tosilate with
beclomethasone dipropionate (BDP), an inhaled ster-
oidal agent that is currently the drug of first choice,
controlled study in patients with mild intermittent
and mild persistent asthma in such treatment.
METHODS
Subjects included 35 mild bronchial asthma outpa-
tients at the Department of Respiratory Tract Medi-
cine, 2nd Education Hospital, Fujita Health University.
The group consisted of 12 men and 23 women 19 to
74 years of age. Atopic asthma was diagnosed in 17
cases and non-atopic asthma in 18 cases , with 13
cases meeting the criteria for step 1 (mild intermit-
tent) asthma and 22 cases for step 2 (mild persistent)
asthma according to the 2003 Guidelines for Preven-
tion and Control of Asthma.6 No patients were using-
bronchodilators or steroidal or anti-allergy drugs (Ta-
ble 1). No significant difference was found between
the two groups in any of these categories.
The study design is shown in Figure 1. All patients
were provided with informed consent and the study
design was approved by the university ethics commit-
tee. After a 2-week run-in period, the patients were
randomly allocated to the suplatast tosilate-treated
group (18 patients) or the BDP-treated group (17 pa-
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Fig. 2　Changes in PEF. Changes in peak expiratory flow during 6 weeks of treat-
ment in adult patients with intermitent and mild persistent asthma: suplatast tosi-
late group (n = 18,100 mg suplatast tosilate three times daily) and BDP group (n = 
17,200 μg BDP twice daily).
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Table 2 Changes in inflammatory markers
Change be-
tween groups
BDPSuplatast tosilate
p valueAfterBeforeAfterBefore
n.s. 4.200±0.646＊5.300±0.7613.769±0.482＊5.385±0.924eosinophils
n.s. 11.07±1.74＊23.17±4.4914.1±2.15＊18.7±3.27serum ECP
p<0.05 (BDP) 327.2±88.3＊＊740.3±185.9307.4±117.6＊627.9±233.5sputum ECP
n.s. 225.1±147.4211.8±127.9170.7±106.7＊184.8±112.2total IgE levels
n.s.2096.6±118.4＊1963.3±130.62388.3±135.3＊2328.3±133.3 FEV1.0
n.s. 4.848±0.808＊3.217±0.6973.087±0.882＊2.393±0.64 Dmin
＊p<0.05 between values ＊＊p<0.01 between values
tients) for 6 weeks of treatment. Suplatast tosilate was
orally administered at a dose of 100 mg three times
daily (total 300 mgday), and BDP was administered
by inhalation at a dose of 200 μg twice daily (total 400
μgday). All patients were asked to keep a journal to
record asthma symptoms. The morning peak expira-
tory flow (PEF) was measured daily, and peripheral
blood eosinophil count, levels of eosinophil cationic
protein (ECP) in serum and induced sputum, total
IgE levels , forced expiratory volume in 1 second
(FEV1.0) , and airway hypersensitivity by the asto-
graph method were measured at baseline and at the
conclusion of the treatment period. Venous blood was
collected and left to stand for 60 minutes at room tem-
perature, after which serum was separated and stored
at − 20℃ or below. Measurements were performed
using the ECP-Kit (Pharmacia Diagnostics, Uppsala,
Sweden). Sputum samples were collected byhyper-
tonic saline induction as described by Pin.7 The spu-
tum was frozen immediately and stored at − 20℃ or
below. At the time of measurement, the saliva portion
was removed. The remaining sample was combined
with 4 volumes of physiological saline (5-fold dilu-
tion), agitated, and then centrifuged at 4000 g for 30
minutes at 4℃ . Measurements were performed on
the supernatant with anECP-Kit. Airway hypersensi-
tivity (Dmin) was determined by astograph (TCK-
6000, Chest Corp., Japan).8
Results are shown as mean ± SD. We used the
Mann-Whitney U test to compare independent data
between the two groups, the Wilcoxon signed rank
test to compare paired data between the two groups,
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and the Friedman test for comparison of paired data
among three or more groups. Intergroup comparison
using the Mann-Whitney U test with Bonferroni cor-
rection was performed on all statistically significant
data．
RESULTS
1) Changes in PEF (Fig. 2)
PEF increased significantly from week 1 in the BDP
group and stabilized after week 2 (P < 0.02). In the
suplatast tosilate group PEF increased significantly
from week 2 (P < 0.03) and reached the nearly the
same maximum level as in the BDP group at week 6
(Fig. 2). However, from week 1 to week 4 the BDP
group showed significantly greater elevation of PEF
than the suplatast tosilate group.
2) Changes in peripheral eosinophil ratio, serum ECP
level, induced sputum ECP level, IgE titer, FEV1.0,
and airway hypersensitivity (Dmin), and comparison
of differences between groups (Table 2).
The peripheral blood eosinophil ratio decreased
significantly after 6 weeks of treatment in both the
suplatast tosilate group (P < 0.02) and the BDP group
(P < 0.02). There was no significant difference in this
change between the two groups.
Serum ECP values also decreased significantly af-
ter 6 weeks of treatment in both groups (suplatast to-
silate P < 0.04, BDP P < 0.02). Again, we found no sig-
nificant difference in change between the two groups.
The induced sputum ECP level decreased signifi-
cantly after 6 weeks of treatment in both the suplatast
tosilate group (P < 0.02 ) and the BDP group
(P < 0.008), with a more pronounced decrease in the
BDP group. A comparison of the difference between
the two groups showed a significantly greater de-
crease in the BDP group.
Total IgE levels decreased significantly after 6
weeks of treatment in the suplatast tosilate group
(P < 0.05) . There was no significant difference in
change between the two groups.
There was a significant increase in FEV1.0 in both
the suplatast tosilate group (P < 0.05) and the BDP
group (P < 0.03) after 6 weeks of treatment. We found
no significant difference in change between the two
groups.
Dmin increased significantly after 6 weeks of treat-
ment in both the suplatast tosilate group (P < 0.05)
and the BDP group (P < 0.02), with no significant dif-
ference in change between the two groups.
DISCUSSION
Allergic inflammation results from a complex interac-
tion between invading cell groups such as mast cells,
eosinophils , basophils , T lymphocytes , and macro-
phages, and local structural cells such as vascular en-
dothelial cells, airway epithelial cells, and fibroblasts.
Conventional explanations of mechanism of onset of
allergic disease have focused on the functions of
eosinophils, mast cells, and basophils, which work as
effectors in allergic inflammation. However, in recent
years the important role of cytokines produced by
lymphocytes, particularly T cells, has become more
obvious.1,2
Helper CD4+ T cells are divided into two subsets,
Th 1 and Th 2. Th 1 cells which mainly produce
interferon-γ and IL-2, are involved in delayed hyper-
sensitivity reactions, cellular immunity, and induction
of IgG2a antibody. Production Th2 cells which pro-
duce IL-4, IL-5, IL-6, and IL-10, are involved in hu-
meral immunity, and induce production of antibodies
such as IgG1 and IgE.9
The onset of the allergic response is attributed to a
shift in the balance between Th1 and Th2 cells, to-
ward excess Th2. As a result, excessive amounts of
IL-4 and IL-5 are available to stimulate production of
IgE antibody by B cells and to promote differentiation
and proliferation of eosinophils . The Th 2-cell-
predominant state appears to play an important role
in the clinical condition of bronchial asthma.10
There has been considerable research on the ef-
fects of suplatast tosilate on Th2 cytokine production.
Findings from experimentally induced asthma in
guinea pigs indicate that suplatast tosilate specifically
inhibited IgE antibody production, and blocked tissue
invasion by eosinophils through the inhibition of IL-4
and IL-5 production . 2,3 Using a mouse model of
asthma, Zhao et al. found that suplatast tosilate inhib-
ited IL-4, IL-5, and IL-13 in bronchoalveolar lavage
fluid, decreased airway invasion by eosinophils, and
reduced airway hypersensitivity.11 Shim et al. also re-
ported that suplatast tosilate inhibited the increase of
IL-4 and IL-13 in bronchoalveolar lavage fluid .12 In
bronchial mucosal biopsy specimens from patients
with bronchial asthma , Sano et al. reported that
suplatast tosilate decreased both the eosinophil count
and the number of cells testing positive for a mono-
clonal antibody to ECP (EG2+).13 In addition, in bron-
chial asthma test findings stratified by degree of se-
verity, Tamaoki et al. reported that suplatast tosilate
was useful for reducing steroid dose in patients with
severe asthma.4 In mild asthma, suplatast tosilate was
reported to inhibit eosinophilic airway inflammation
and airway hypersensitivity by significantly reducing
peripheral blood eosinophils, serum ECP levels, and
induced sputum ECP levels.5 These results were par-
ticularly prominent in cases of atopic asthma.
In our study we compared the therapeutic effects
of suplatast tosilate and BDP in patients with mild
bronchial asthma. Criteria for mild bronchial asthma
as defined at step 1 is the presence of airway hyper-
sensitivity and chronic airway inflammation , even
though asthma symptoms may be mild.6 This study
involved patients who met the criteria for either step
1 or step 2.
The suplatast tosilate group required more time to
show improvements in PEF than the BDP group .
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BDP was associated with significantly higher PEF
values than suplatast tosilate during weeks 1 through
4, but suplatast tosilate results were almost identical
to those for BDP by the fifth or sixth week . The
suplatast tosilate group also showed significant im-
provements in the peripheral blood eosinophil ratio,
ECP levels in serum and induced sputum, total IgE
levels, FEV1.0, and Dmin. The BDP group had lower
levels of induced sputum ECP, a parameter closely
associated with damage to the airway mucosa as a re-
sult of inflammation. Total IgE levels were inhibited
only in the suplatast tosilate group. Although the dif-
ferences between baseline and posttreatment find-
ings was not statistically significant in either group,
these findings show that oral suplatast tosilate de-
creased total IgE levels, an effect not demonstrated
with inhaled steroids. A comparison of baseline and
posttreatment findings in the suplatast tosilate group
and the BDP group also showed that BDP was associ-
ated with a significantly greater improvement than
suplatast tosilate in sputum ECP levels only. These
findings suggest that by decreasing the level of
eosinophil ECP in peripheral blood, suplatast tosilate
inhibited eosinophilic inflammation of the airway and
thus blocked the development of airway hypersensi-
tivity.
These results suggest that oral suplatast tosilate
has nearly the same therapeutic usefulness as in-
haled BDP 400 μgday in patients with mild asthma.
However , long-term management of bronchial
asthma, there is no doubt that inhaled steroids are
the treatment of first choice. The results of this study
suggest that suplatast tosilate may become a first-line
treatment option for mild asthma . In cases where
there are problems with compliance when using in-
haled steroids, limits on the use of inhaled steroids,
concerns about local or systemic adverse reactions
from inhaled steroids, or complications of allergic si-
nusitis or atopic dermatitis , suplatast tosilate may
prove useful in the long-term management of bron-
chial asthma. Further study of the drug’s long-term
effects are needed．
CONCLUSION
We prospectively compared the therapeutic effects of
suplatast tosilate and BDP in 35 patients with inter-
mittent and mild persistent asthma by randomly allo-
cating patients a suplatast tosilate group (18 patients,
100 mg three times daily) or a BDP group (17 pa-
tients, 200 μg twice daily) for 6 weeks of treatment.
1. The suplatast tosilate group required more time
than the BDP group to show improvements in PEF.
BDP treatment was associated with significantly
higher PEF values during weeks 1 through 4, but
suplatast tosilate showed results almost identical to
those for BDP by the fifth or sixth week.
2. Both groups showed significant improvement in
the peripheral blood eosinophil ratio, serum ECP lev-
els, induced sputum ECP levels, FEV1.0, and Dmin.
However, induced sputum ECP levels were lower in
the BDP group than in the suplatast tosilate group.
3. Total IgE levels decreased only in the suplatast
tosilate group.
We conclude that suplatast tosilate may be useful
in the long-term management of mild bronchial
asthma．
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